Exelixis (EXEL) Receives Media Impact Rating of 0.19
Headlines about Exelixis (NASDAQ:EXEL) have been trending somewhat positive on Tuesday, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exelixis earned a news impact score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.3190995967884 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s analysis:
- Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run (investorplace.com)
- Exelixis, Inc. (EXEL) Expected to Post Quarterly Sales of $117.71 Million (americanbankingnews.com)
- Financial Comparison: Exelixis (EXEL) and The Competition (americanbankingnews.com)
- Zacks: Analysts Expect Exelixis, Inc. (EXEL) to Post $0.12 EPS (americanbankingnews.com)
- Renal Cell Cacinoma Drugs Analysis and Forecasts, Present Scenario and Growth Prospects, Trends and Challenges according to New Research Report 2022 (medgadget.com)
EXEL has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research note on Tuesday, October 10th. SunTrust Banks raised their price objective on shares of Exelixis from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Needham & Company LLC raised their price objective on shares of Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, October 17th. BidaskClub raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 25th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Exelixis in a research note on Monday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $31.38.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.18. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The firm had revenue of $152.50 million during the quarter, compared to analyst estimates of $104.91 million. During the same quarter last year, the business posted ($0.04) EPS. The company’s revenue was up 145.2% on a year-over-year basis. research analysts expect that Exelixis will post 0.49 earnings per share for the current year.
In other Exelixis news, insider Gisela Schwab sold 100,000 shares of the stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $23.79, for a total value of $2,379,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey Hessekiel sold 27,302 shares of the stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $24.28, for a total transaction of $662,892.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 870,152 shares of company stock valued at $23,244,457. Insiders own 5.10% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Stock Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related stocks with our FREE daily email newsletter.